236 related articles for article (PubMed ID: 23242435)
21. Pemetrexed induced thymidylate synthase inhibition in non-small cell lung cancer patients: a pilot study with 3'-deoxy-3'-[¹⁸F]fluorothymidine positron emission tomography.
Frings V; van der Veldt AA; Boellaard R; Herder GJ; Giovannetti E; Honeywell R; Peters GJ; Thunnissen E; Hoekstra OS; Smit EF
PLoS One; 2013; 8(5):e63705. PubMed ID: 23717468
[TBL] [Abstract][Full Text] [Related]
22. Second-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer: a randomized, open-label study.
Sun Y; Wu YL; Zhou CC; Zhang L; Zhang L; Liu XY; Yu SY; Jiang GL; Li K; Qin SK; Ma SL; Han L; Quinlivan M; Orlando M; Zhang XQ
Lung Cancer; 2013 Feb; 79(2):143-50. PubMed ID: 23182660
[TBL] [Abstract][Full Text] [Related]
23. Expression and pharmacological inhibition of thymidylate synthase and Src kinase in nonsmall cell lung cancer.
Ceppi P; Rapa I; Lo Iacono M; Righi L; Giorcelli J; Pautasso M; Billè A; Ardissone F; Papotti M; Scagliotti GV
Int J Cancer; 2012 Apr; 130(8):1777-86. PubMed ID: 21618517
[TBL] [Abstract][Full Text] [Related]
24. Reduced folate carrier and folylpolyglutamate synthetase, but not thymidylate synthase predict survival in pemetrexed-treated patients suffering from malignant pleural mesothelioma.
Mairinger F; Vollbrecht C; Halbwedl I; Hatz M; Stacher E; Gülly C; Quehenberger F; Stephan-Falkenau S; Kollmeier J; Roth A; Mairinger T; Popper H
J Thorac Oncol; 2013 May; 8(5):644-53. PubMed ID: 23449276
[TBL] [Abstract][Full Text] [Related]
25. Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression.
Cardona AF; Rojas L; Wills B; Arrieta O; Carranza H; Vargas C; Otero J; Cuello M; Corrales L; Martín C; Ortiz C; Franco S; Rosell R;
PLoS One; 2016; 11(5):e0154293. PubMed ID: 27191954
[TBL] [Abstract][Full Text] [Related]
26. [Effect of pemetrexed plus platinum for chemotherapy-naive advanced non-small cell lung cancer].
Duan JC; Wu MN; Zhao J; An TT; Yang L; Bai H; Wang ZJ; Zhuo ML; Wang SH; Wang YY; Liu XH; Wang J
Zhonghua Jie He He Hu Xi Za Zhi; 2012 Feb; 35(2):97-101. PubMed ID: 22455964
[TBL] [Abstract][Full Text] [Related]
27. Thymidylate synthase polymorphisms in genomic DNA as clinical outcome predictors in a European population of advanced non-small cell lung cancer patients receiving pemetrexed.
Arévalo E; Castañón E; López I; Salgado J; Collado V; Santisteban M; Rodríguez-Ruiz M; Martín P; Zubiri L; Patiño-García A; Rolfo C; Gil-Bazo I
J Transl Med; 2014 Apr; 12():98. PubMed ID: 24726028
[TBL] [Abstract][Full Text] [Related]
28. The Predictive Value of ERCC1, RRM1, and Thymidylate Synthase in Advanced Malignant Pleural Mesothelioma Patients Treated with Platinum-Based Chemotherapy.
Wahba NI; Khorshid O; Abo Elkasem F; Bahnassy A; Gaafer R
Asian Pac J Cancer Prev; 2023 Jan; 24(1):195-205. PubMed ID: 36708568
[TBL] [Abstract][Full Text] [Related]
29. Thymidylate synthase and folyl-polyglutamate synthase are not clinically useful markers of response to pemetrexed in patients with malignant pleural mesothelioma.
Lustgarten DE; Deshpande C; Aggarwal C; Wang LC; Saloura V; Vachani A; Wang LP; Litzky L; Feldman M; Creaney J; Nowak AK; Langer C; Inghilleri S; Stella G; Albelda SM
J Thorac Oncol; 2013 Apr; 8(4):469-77. PubMed ID: 23486267
[TBL] [Abstract][Full Text] [Related]
30. Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer.
Lee JO; Kim TM; Lee SH; Kim DW; Kim S; Jeon YK; Chung DH; Kim WH; Kim YT; Yang SC; Kim YW; Heo DS; Bang YJ
J Thorac Oncol; 2011 Sep; 6(9):1474-80. PubMed ID: 21642865
[TBL] [Abstract][Full Text] [Related]
31. A randomised phase II study of pemetrexed versus pemetrexed+erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer.
Dittrich C; Papai-Szekely Z; Vinolas N; Sederholm C; Hartmann JT; Behringer D; Kazeem G; Desaiah D; Leschinger MI; von Pawel J
Eur J Cancer; 2014 Jun; 50(9):1571-80. PubMed ID: 24703574
[TBL] [Abstract][Full Text] [Related]
32. Approval summary: pemetrexed maintenance therapy of advanced/metastatic nonsquamous, non-small cell lung cancer (NSCLC).
Cohen MH; Cortazar P; Justice R; Pazdur R
Oncologist; 2010; 15(12):1352-8. PubMed ID: 21148615
[TBL] [Abstract][Full Text] [Related]
33. Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer.
Smit EF; Socinski MA; Mullaney BP; Myrand SP; Scagliotti GV; Lorigan P; Reck M; Ciuleanu T; von Pawel J; Karaseva NA; Szczesna A; Ohannesian D; Powell E; Hozak RR; Hong S; Guba SC; Thatcher N
Ann Oncol; 2012 Jul; 23(7):1723-9. PubMed ID: 22186609
[TBL] [Abstract][Full Text] [Related]
34. Identifying the target NSCLC patient for maintenance therapy: an analysis from a placebo-controlled, phase III trial of maintenance pemetrexed (H3E-MC-JMEN).
Obasaju C; Bowman L; Wang P; Shen W; Winfree KB; Smyth EN; Boye ME; John W; Brodowicz T; Belani CP
Ann Oncol; 2013 Jun; 24(6):1534-42. PubMed ID: 23559150
[TBL] [Abstract][Full Text] [Related]
35. [Impact of histology on efficacy of pemetrexed: pemetrexed in second-line setting and as maintenance therapy after first-line treatment in Chinese patients with advanced NSCLC].
Zhou C; Wu Y; Sun Y; Wang Y; Wang X; Zhang X
Zhonghua Zhong Liu Za Zhi; 2014 Jan; 36(1):29-33. PubMed ID: 24685083
[TBL] [Abstract][Full Text] [Related]
36. [Thymidylate synthase expression and therapeutic effect analysis of pemetrexed in advanced lung adenocarcinoma].
Wang ZK; Hu Y; Zhao H; Fu C
Nan Fang Yi Ke Da Xue Xue Bao; 2010 May; 30(5):978-80. PubMed ID: 20501373
[TBL] [Abstract][Full Text] [Related]
37. Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin.
Zucali PA; Giovannetti E; Destro A; Mencoboni M; Ceresoli GL; Gianoncelli L; Lorenzi E; De Vincenzo F; Simonelli M; Perrino M; Bruzzone A; Thunnissen E; Tunesi G; Giordano L; Roncalli M; Peters GJ; Santoro A
Clin Cancer Res; 2011 Apr; 17(8):2581-90. PubMed ID: 21262916
[TBL] [Abstract][Full Text] [Related]
38. The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer.
Chang MH; Ahn JS; Lee J; Kim KH; Park YH; Han J; Ahn MJ; Park K
Lung Cancer; 2010 Sep; 69(3):323-9. PubMed ID: 20061047
[TBL] [Abstract][Full Text] [Related]
39. Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural mesothelioma.
Christoph DC; Asuncion BR; Mascaux C; Tran C; Lu X; Wynes MW; Gauler TC; Wohlschlaeger J; Theegarten D; Neumann V; Hepp R; Welter S; Stamatis G; Tannapfel A; Schuler M; Eberhardt WE; Hirsch FR
J Thorac Oncol; 2012 Sep; 7(9):1440-8. PubMed ID: 22895141
[TBL] [Abstract][Full Text] [Related]
40. Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer.
Takezawa K; Okamoto I; Okamoto W; Takeda M; Sakai K; Tsukioka S; Kuwata K; Yamaguchi H; Nishio K; Nakagawa K
Br J Cancer; 2011 May; 104(10):1594-601. PubMed ID: 21487406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]